Spero Therapeutics (NASDAQ:SPRO) Stock Crosses Below Two Hundred Day Moving Average – Should You Sell?

Shares of Spero Therapeutics, Inc. (NASDAQ:SPRO) crossed below its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $1.23 and traded as low as $0.85. Spero Therapeutics shares last traded at $0.91, with a volume of 371,185 shares traded.

Wall Street Analyst Weigh In

A number of research firms have issued reports on SPRO. Evercore ISI cut Spero Therapeutics from an “outperform” rating to an “in-line” rating and set a $5.00 target price on the stock. in a research report on Friday, December 20th. TD Cowen reaffirmed a “hold” rating on shares of Spero Therapeutics in a report on Monday, November 18th. Cantor Fitzgerald reissued an “overweight” rating on shares of Spero Therapeutics in a research note on Friday, November 15th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $5.00 target price on shares of Spero Therapeutics in a research note on Monday, December 2nd.

Spero Therapeutics Stock Up 9.0 %

The stock has a market capitalization of $49.61 million, a price-to-earnings ratio of 13.00 and a beta of 0.63. The stock has a 50 day moving average price of $1.07 and a 200 day moving average price of $1.23.

Institutional Investors Weigh In On Spero Therapeutics

A hedge fund recently raised its stake in Spero Therapeutics stock. Renaissance Technologies LLC grew its holdings in shares of Spero Therapeutics, Inc. (NASDAQ:SPRO) by 14.2% in the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 975,952 shares of the company’s stock after acquiring an additional 121,492 shares during the period. Renaissance Technologies LLC owned about 1.81% of Spero Therapeutics worth $1,269,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 25.60% of the company’s stock.

About Spero Therapeutics

Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company’s product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease.